First Tracks Biotherapeutics up after $200 mln equity raise

** Shares of First Tracks Biotherapeutics TRAX.O up 2.8% to $35.08 premarket on Thurs after securing $200 mln equity raise

** TRAX says it sold ~6.1 mln shares in private placement to group of new and existing investors at $32.75

** Co intends to use net proceeds from the placement for general corporate purposes, including for clinical development of ANB033

** Leerink, Piper Sandler, UBS and Wells Fargo are placement agents

** On Mon, TRAX stock finished up ~7% at $34.05 after co announced positive top-line results for ANB033 in celiac disease drug trial

** San Diego, California-based firm has ~35.7 mln shares outstanding

** On Apr 20, TRAX stock closed at $18.60 in its Nasdaq debut after co was spun out of AnaptysBio ANAB.O

** All 12 analysts covering TRAX are bullish including 4 "strong buy" ratings on the stock; median PT of $70 up from $44 three months ago, per LSEG